Long‐Sheng Chang

5.8k total citations · 2 hit papers
82 papers, 4.6k citations indexed

About

Long‐Sheng Chang is a scholar working on Molecular Biology, Neurology and Oncology. According to data from OpenAlex, Long‐Sheng Chang has authored 82 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Molecular Biology, 35 papers in Neurology and 25 papers in Oncology. Recurrent topics in Long‐Sheng Chang's work include Neurofibromatosis and Schwannoma Cases (35 papers), Meningioma and schwannoma management (21 papers) and Virus-based gene therapy research (11 papers). Long‐Sheng Chang is often cited by papers focused on Neurofibromatosis and Schwannoma Cases (35 papers), Meningioma and schwannoma management (21 papers) and Virus-based gene therapy research (11 papers). Long‐Sheng Chang collaborates with scholars based in United States, Russia and Japan. Long‐Sheng Chang's co-authors include Thomas Shenk, R. Jude Samulski, Edward Seto, Yang Shi, D. Bradley Welling, Elena M. Akhmametyeva, Lingyun Zhao, Yanhong Shi, Mien‐Chie Hung and Duen‐Hwa Yan and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Long‐Sheng Chang

79 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Transcriptional repression by YY1, a human GLI-Krüippel-related protein, and relief of repression by adenovirus E1A protein

1991 932 citations Long‐Sheng Chang et al. Cell profile →
Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression

1989 617 citations Long‐Sheng Chang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Long‐Sheng Chang United States	34	2.9k	1.6k	1.0k	711	571	82	4.6k
Laurent Schaeffer France	37	4.5k 1.5×	552 0.3×	926 0.9×	298 0.4×	521 0.9×	105	5.5k
Naoko Tanese United States	34	4.2k 1.4×	558 0.3×	343 0.3×	571 0.8×	439 0.8×	55	5.3k
Harald Petry Germany	37	1.9k 0.6×	1.3k 0.8×	647 0.6×	480 0.7×	186 0.3×	93	3.4k
Romain Zufferey Switzerland	22	5.7k 1.9×	4.4k 2.7×	1.2k 1.2×	744 1.0×	310 0.5×	30	8.2k
János Sümegi United States	40	3.2k 1.1×	788 0.5×	1.2k 1.2×	349 0.5×	223 0.4×	138	6.0k
Richard O. Snyder United States	38	3.9k 1.3×	3.8k 2.3×	863 0.9×	489 0.7×	211 0.4×	64	5.4k
Masashi Urabe Japan	29	2.2k 0.7×	1.7k 1.0×	547 0.5×	308 0.4×	161 0.3×	98	3.3k
Ya‐Wen Chiang United States	26	2.6k 0.9×	2.6k 1.6×	1.3k 1.3×	502 0.7×	222 0.4×	42	4.5k
Peter C. Scacheri United States	41	4.8k 1.6×	1.0k 0.6×	769 0.8×	715 1.0×	399 0.7×	80	6.5k
Tomoki Todo Japan	43	3.1k 1.1×	3.4k 2.1×	2.8k 2.8×	1.8k 2.5×	590 1.0×	143	7.2k

Countries citing papers authored by Long‐Sheng Chang

Since Specialization

Citations

This map shows the geographic impact of Long‐Sheng Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Long‐Sheng Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Long‐Sheng Chang more than expected).

Fields of papers citing papers by Long‐Sheng Chang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Long‐Sheng Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Long‐Sheng Chang. The network helps show where Long‐Sheng Chang may publish in the future.

Co-authorship network of co-authors of Long‐Sheng Chang

This figure shows the co-authorship network connecting the top 25 collaborators of Long‐Sheng Chang. A scholar is included among the top collaborators of Long‐Sheng Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Long‐Sheng Chang. Long‐Sheng Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wood, Christopher G., Anat Stemmer‐Rachamimov, Daniel J. Lee, et al.. (2025). Increased Hemorrhage During Excision of Bevacizumab‐Treated NF2 ‐Related Vestibular Schwannomas. The Laryngoscope. 135(11). 4355–4363.

Oblinger, Janet L., Roberta L. Beauchamp, Françis Robert, et al.. (2024). Preclinical evaluation of the third-generation, bi-steric mechanistic target of rapamycin complex 1-selective inhibitor RMC-6272 in NF2-deficient models. Neuro-Oncology Advances. 6(1). vdae024–vdae024.

Oblinger, Janet L., Garima Agarwal, Joelle M. Fenger, et al.. (2024). Anti-tumor effects of the eIF4A inhibitor didesmethylrocaglamide and its derivatives in human and canine osteosarcomas. Scientific Reports. 14(1). 19349–19349. 1 indexed citations

Chang, Long‐Sheng, et al.. (2023). Impact of Consolidative Radiation on Overall and Progression Free Survival in Pediatric, Adolescent and Young Adult Metastatic Sarcoma. International Journal of Radiation Oncology*Biology*Physics. 117(2). S132–S133.

Welling, D. Bradley, Katharine A. Collier, Sarah S. Burns, et al.. (2021). Early phase clinical studies of AR‐42, a histone deacetylase inhibitor, for neurofibromatosis type 2‐associated vestibular schwannomas and meningiomas. Laryngoscope Investigative Otolaryngology. 6(5). 1008–1019. 24 indexed citations

Chang, Long‐Sheng, Janet L. Oblinger, Sarah S. Burns, et al.. (2019). Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas. Molecular Cancer Therapeutics. 19(3). 731–741. 16 indexed citations

Burns, Sarah S., Christine T. Dinh, Denise Yan, et al.. (2017). Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells. Molecular Cancer Therapeutics. 16(11). 2387–2398. 25 indexed citations

Spear, Samuel A., Sarah S. Burns, Janet L. Oblinger, et al.. (2013). Natural Compounds as Potential Treatments of NF2-Deficient Schwannoma and Meningioma. Otology & Neurotology. 34(8). 1519–1527. 23 indexed citations

Burns, Sarah S., Elena M. Akhmametyeva, Janet L. Oblinger, et al.. (2012). Histone Deacetylase Inhibitor AR-42 Differentially Affects Cell-cycle Transit in Meningeal and Meningioma Cells, Potently Inhibiting NF2 -Deficient Meningioma Growth. Cancer Research. 73(2). 792–803. 38 indexed citations

10.

Wang, Yuan, Edward Kim, Xiaojing Wang, et al.. (2012). ERK Inhibition Rescues Defects in Fate Specification of Nf1-Deficient Neural Progenitors and Brain Abnormalities. Cell. 150(4). 816–830. 112 indexed citations

11.

Welling, D. Bradley, Mark D. Packer, & Long‐Sheng Chang. (2007). Molecular studies of vestibular schwannomas: a review. Current Opinion in Otolaryngology & Head & Neck Surgery. 15(5). 341–346. 23 indexed citations

12.

Neff, Brian A., et al.. (2006). Cyclin D₁ and D₃ Expression in Vestibular Schwannomas. The Laryngoscope. 116(3). 423–426. 11 indexed citations

13.

Chang, Long‐Sheng, Jacob Abraham, Jonathan Rock, et al.. (2006). Growth of Benign and Malignant Schwannoma Xenografts in Severe Combined Immunodeficiency Mice. The Laryngoscope. 116(11). 2018–2026. 21 indexed citations

14.

O’Neill, Kim L., et al.. (2005). Development of a novel human vestibular schwannoma xenograft model in SCID mice. Cancer Research. 65. 1394–1394. 1 indexed citations

15.

Xu, Zhixiong, Suming Huang, Long‐Sheng Chang, Alan D. Agulnick, & Stephen J. Brandt. (2003). Identification of a TAL1 Target Gene Reveals a Positive Role for the LIM Domain-Binding Protein Ldb1 in Erythroid Gene Expression and Differentiation. Molecular and Cellular Biology. 23(21). 7585–7599. 121 indexed citations

16.

Lee, Yuandan, Yan Chen, Long‐Sheng Chang, & Lee F. Johnson. (1997). Inhibition of Mouse Thymidylate Synthase Promoter Activity by the Wild-Type p53 Tumor Suppressor Protein. Experimental Cell Research. 234(2). 270–276. 41 indexed citations

17.

Chang, Long‐Sheng, et al.. (1995). Differential Roles of Two Tandem E2F Sites in Repression of the Human p107 Promoter by Retinoblastoma and p107 Proteins. Molecular and Cellular Biology. 15(7). 3552–3562. 103 indexed citations

18.

Karaçay, Bahri, et al.. (1995). The murine erythrocyte protein-4.2-encoding gene: similarities and differences in structure and expression from its human counterpart. Gene. 158(2). 253–256. 2 indexed citations

19.

Chang, Long‐Sheng, et al.. (1995). Structure of the Gene for the Catalytic Subunit of Human DNA Polymerase δ (POLD1). Genomics. 28(3). 411–419. 25 indexed citations

20.

Yan, Duen‐Hwa, Long‐Sheng Chang, & Mien‐Chie Hung. (1991). Repressed expression of the HER-2/c-erbB-2 proto-oncogene by the adenovirus E1a gene products.. PubMed. 6(2). 343–5. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact